Markets.com Logo
markets.com

ESPR

$--
--%
1d
1w
1m

Analysis and statistics

  • Open
    2.0751$
  • Previous Close
    2.1458$
  • 52 Week Change
    3.25$
  • Day Range
    -0.07$
  • 52 Week High/Low
    0.6925$ - 3.94$
  • Dividend Per Share
    --
  • Market cap
    413 M$
  • EPS
    -0.02
  • Beta
    0.825
  • Volume
    --

About

ESPR.US refers to Esperion Therapeutics, Inc., a pharmaceutical company focused on developing and commercializing non-statin, oral therapies for the treatment of elevated low-density lipoprotein cholesterol (LDL-C), also known as "bad cholesterol." The company's primary products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) which are approved to lower LDL-C in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional LDL-C lowering. Esperion Therapeutics is listed on the Nasdaq Stock Market under the ticker symbol ESPR.
markets.com

Factors

Company Performance: Earnings reports, clinical trial results, and product launches all heavily influence investor sentiment and stock price.

Market Conditions: Broader market trends, such as economic growth, interest rates, and investor risk appetite, can impact all stocks, including ESPR.US.

Regulatory Approvals: FDA decisions regarding Esperion's drugs directly affect revenue potential and stock value.

Competition: The presence and success of competing cholesterol-lowering medications impact market share and ESPR.US's prospects.

Partnerships/Deals: Strategic collaborations, licensing agreements, or acquisitions can boost confidence and share price.

News & Developments: Unexpected positive or negative news related to Esperion can cause price volatility.

Analyst Ratings: Recommendations and price targets from financial analysts can influence investor decisions.

People Also Watch

Latest news

BTC Surges 8% Toward $77,000 as Short Squeeze Accelerates

BTC Surges 8% Toward $77,000 as Short Squeeze Accelerates

Julian Parker|--
SK Hynix Stock Outperforms KOSPI on Report of Potential Japan Memory Fab

SK Hynix Stock Outperforms KOSPI on Report of Potential Japan Memory Fab

Julian Parker|--
WTI Near $87 as Iran Sanctions Risk Lifts Crude

WTI Near $87 as Iran Sanctions Risk Lifts Crude

Julian Parker|--

Latest Education Articles

How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

How to Trade Gold CFDs: A Beginner’s Guide to XAU/USD Trading

Daniel Carter|--
How to Read a Forex Chart: A Beginner’s Guide to Candlesticks and Trends

How to Read a Forex Chart: A Beginner’s Guide to Candlesticks and Trends

Daniel Carter|--
Forex Risk Management: 10 Strategies Every Trader Should Know

Forex Risk Management: 10 Strategies Every Trader Should Know

Daniel Carter|--
Recommended Topics
markets.com